This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BDSI BioDelivery Sciences International (BDSI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioDelivery Sciences International Stock (NASDAQ:BDSI) 30 days 90 days 365 days Advanced Chart Remove Ads Get BDSI alerts:Sign Up Key Stats Today's Range N/A50-Day Range$5.54▼$5.6052-Week Range N/AVolume2.09 million shsAverage Volume3.34 million shsMarket Capitalization$577.05 millionP/E Ratio6.74Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.Read More… Remove Ads Receive BDSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSI Stock News HeadlinesFlorida International UniversitySeptember 14, 2023 | usnews.comInternational High School for Health SciencesMay 6, 2023 | usnews.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 5, 2025 | Porter & Company (Ad)International climate change bodies win humanity awardOctober 15, 2022 | omaha.comPerilous Reversal Watch: BioDelivery Sciences International (BDSI)September 16, 2022 | thestreet.comScienceSeptember 13, 2022 | npr.orgCollegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | seekingalpha.comJim Cramer's Top Stock Picks: DF MNST BDSIMay 2, 2022 | thestreet.comSee More Headlines BDSI Stock Analysis - Frequently Asked Questions How were BioDelivery Sciences International's earnings last quarter? BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to the consensus estimate of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%. What other stocks do shareholders of BioDelivery Sciences International own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioDelivery Sciences International investors own include NVIDIA (NVDA), Bristol-Myers Squibb (BMY), TG Therapeutics (TGTX), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/02/2021Today4/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BDSI CIK1103021 Webwww.bdsi.com Phone(919) 582-9050Fax919-582-9051Employees200Year Founded1997Profitability EPS (Most Recent Fiscal Year)$0.83 Trailing P/E Ratio6.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$84.86 million Net Margins50.90% Pretax Margin17.77% Return on Equity21.25% Return on Assets10.56% Debt Debt-to-Equity Ratio0.29 Current Ratio2.45 Quick Ratio2.17 Sales & Book Value Annual Sales$166.70 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow15.42 Book Value$1.90 per share Price / BookN/AMiscellaneous Outstanding Shares103,229,000Free Float92,927,000Market Cap$577.05 million OptionableOptionable Beta0.56 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:BDSI) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioDelivery Sciences International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioDelivery Sciences International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.